Research Analysts Issue Forecasts for TENX FY2025 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Stock analysts at Roth Capital lowered their FY2025 EPS estimates for shares of Tenax Therapeutics in a report issued on Wednesday, November 12th. Roth Capital analyst J. Aschoff now expects that the specialty pharmaceutical company will post earnings of ($1.39) per share for the year, down from their prior estimate of ($1.17). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q4 2025 earnings at ($0.43) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at $1.76 EPS and FY2029 earnings at $3.34 EPS.

Tenax Therapeutics (NASDAQ:TENX) last issued its earnings results on Wednesday, November 12th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.93.

A number of other equities research analysts have also weighed in on the company. Piper Sandler assumed coverage on Tenax Therapeutics in a research note on Monday, September 8th. They issued an “overweight” rating and a $20.00 target price for the company. Wall Street Zen upgraded Tenax Therapeutics to a “sell” rating in a research report on Saturday, October 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tenax Therapeutics in a research note on Tuesday, November 11th. Finally, Guggenheim decreased their target price on shares of Tenax Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, August 14th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Tenax Therapeutics has an average rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Stock Up 3.5%

NASDAQ TENX opened at $7.35 on Monday. The company has a 50-day simple moving average of $7.02 and a two-hundred day simple moving average of $6.31. Tenax Therapeutics has a 12-month low of $4.63 and a 12-month high of $8.24. The firm has a market cap of $33.54 million, a price-to-earnings ratio of -7.99 and a beta of 1.52.

Hedge Funds Weigh In On Tenax Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC lifted its position in Tenax Therapeutics by 98.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock valued at $450,000 after acquiring an additional 34,048 shares during the period. Woodline Partners LP purchased a new position in Tenax Therapeutics during the third quarter valued at $671,000. Millennium Management LLC boosted its holdings in Tenax Therapeutics by 34.2% in the third quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company’s stock worth $2,387,000 after acquiring an additional 79,998 shares in the last quarter. Citadel Advisors LLC grew its stake in shares of Tenax Therapeutics by 318.1% in the third quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company’s stock worth $329,000 after acquiring an additional 32,908 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Tenax Therapeutics during the third quarter valued at $92,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.